Navigation Links
Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Date:6/5/2008

thy volunteers to the CAD patient population," stated Doug Gooding, Chief Executive Officer of Regado Biosciences. "Following the completion of a Phase 1 program in a total of 173 patients, the Company now is evaluating this first-in-class antidote-reversible therapeutic system in a Phase 2a trial in patients undergoing elective percutaneous coronary intervention. If the results of this study further confirm the Phase 1 data, we are confident this system may be able to transform the way anticoagulation is approached in coronary revascularization procedures and other acute care settings."

Data from Regado's Phase 1b study were presented previously at the American Heart Association's 2007 Scientific Sessions.

About REG1 Anticoagulation System Clinical Program

Regado's Phase 1 program included three studies. A Phase 1a study enrolled 84 healthy volunteers, while the Phase 1b study reported above enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. In addition, the Company conducted a Phase 1c clinical study, in which 39 healthy volunteers were randomized to receive either three consecutive REG1 treatment cycles or placebo. The Phase 1c study further demonstrated RB007's ability to reverse the anticoagulant effect of RB006 either completely or partially, depending on the level of dosing of RB007.

Based upon the combined results of the Company's Phase 1a, 1b, and 1c studies, Regado initiated REVERSAL-PCI, a multi-center, open-label, randomized Phase 2a clinical study of the REG1 anticoagulation system. The Phase 2a study is enrolling 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting in patients at low risk for complications associated with therapy-related bleeding or heart attack.

About REG1 Anticoagulation System


'/>"/>
SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
4. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
5. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
6. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
7. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
8. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
9. Neurocrine Biosciences Reports First Quarter 2008 Results
10. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... December 17, 2014 Los beneficios ... un alto nivel de gasto en investigación y desarrollo ... (finalizado el 30 de septiembre de 2014) ZEISS aumentó ... millones de euros (año anterior: 4.190 millones de euros) ... Las ganancias (EBIT) crecieron un 14 por ciento, a ...
(Date:12/17/2014)... , Dec. 17, 2014 With advancements ... the MRI market is seeing new growth, according ... MRI scans account for the majority of market ... resolution of images, which are creating opportunities for more ... market is growing at a rate of 4%, ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... 14, 2011  Heska Corporation (NASDAQ: HSKA ; ... and specialty products to veterinarians, announced today the intent ... expertise in blood-related disorders.  The parties are to explore ... cell-based therapeutics, for use in the veterinary market.      ...
... Group, Inc. (OTCMARKETS: UYMG) "UNITY" (or the "Company"), and its ... it has sold its initial PZ Uno Tablet press to ... the company is not able to disclose the name of ... tablet press would be used for a research and development ...
Cached Medicine Technology:Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 2Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 3Unity Management Group, Inc. Announces Its Initial Sale of the PZ UNO Tablet Press to a Major Pharmaceutical Company for $500,000 2
(Date:12/20/2014)... December 20, 2014 Weddingshe.com has recently ... launched a site-wide promotion of special occasion dresses for ... popular supplier of special occasion dresses for global women. ... with big discounts, up to 80% off. Among the ... Sequins Short Sweet 16 Dress) is very popular. What’s ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
(Date:12/20/2014)... 20, 2014 Recently, VogueQueen.com, a leading ... VogueQueen Big Sale Online for 2015. Great discounts ... new and old consumers can get a discount, up ... the company’s website before January 30, 2015. , VogueQueen.com ... and launched a prom dress promotion. Many customers worldwide ...
(Date:12/20/2014)... York (PRWEB) December 20, 2014 ... to move forward in U.S. courts, Bernstein Liebhard ... which suggests that children treated with the medication ... linked to breast development and lactation. The study, ... 34 children and adolescents who began treatment with ...
(Date:12/20/2014)... Recently, AngelWeddingDress.com has introduced its special offer ... coming Christmas. In the promotion, all buyers worldwide can ... have something special for the women who are looking ... our new collections of 2015 dresses have been unveiled ... greatly discounted prices. Visit our website now before they ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... with early rheumatoid arthritis (RA) who are current smokers were ... tumor necrosis factor (TNF) inhibitors than those who never smoked. ... patients who smoked in the past did not experience a ... appear in the January 2011 issue of Arthritis & ...
... is potentially more potent, longer lasting and less ... study led by a Loyola University Health System ... a similar chemical structure to standard morphine. Dr. ... study they performed in rats "demonstrated potential clinical ...
... glaucoma tests requiring a visit to the ophthalmologist could ... by an engineer at the University of Arizona. ... sensors, specially designed microchips, and math-based programmed procedures has ... Engineering. The easy-to-use probe gently rubs the eyelid and ...
... from Virginia Mason Medical Center in Seattle, WA, have ... inappropriate medical imaging, including unnecessary computed tomography (CT) and ... in the January issue of the Journal of ... "Clinical decision support systems are point-of-order decision ...
... clinicians frequently use portable media (CDs, DVDs) to review ... magnetic resonance imaging (MRI) and computed tomography (CT) scans, ... portable media exist, according to a study in the ... College of Radiology ( www.jacr.org ). "Because ...
... DATA SHOWS OMALIZUMAB SAFE AND EFFECTIVE FOR MODERATE TO SEVERE ... New research suggests that subcutaneous omalizumab is safe and effective ... in children and adults. Researchers from Uruguay, Argentina, and Chile ... omalizumab and 1,546 received a placebo. At the end of ...
Cached Medicine News:Health News:Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate 2Health News:Experimental drug more potent, longer lasting than morphine 2Health News:New glaucoma test allows earlier, more accurate detection 2Health News:Study finds problems with reviewing medical images from portable media 2Health News:News briefs from the January issue of Chest 2
... a cruciate sparing version which provides ... both resurfacing and inset patellas. Precision ... and fit with tibial articular surface ... cutting guide peg locations provide easy ...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
... The Duracon tibial inserts have radiused ... advanced 4-axis machining, maximizing conformity of ... condyles of the femoral component. The ... the Duracon system, and accommodates the ...
Medicine Products: